Vical (NASDAQ:VICL) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Thursday, May 10th.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
Several other research analysts also recently commented on VICL. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Vical in a research report on Friday, March 16th. ValuEngine raised shares of Vical from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Vical currently has a consensus rating of “Hold” and a consensus target price of $5.25.
Vical (NASDAQ:VICL) last announced its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.29) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.12). Vical had a negative net margin of 144.80% and a negative return on equity of 32.93%. The company had revenue of $0.72 million during the quarter, compared to the consensus estimate of $2.10 million. analysts expect that Vical will post -1.08 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Armistice Capital LLC acquired a new stake in shares of Vical in the 4th quarter worth about $3,660,000. BVF Inc. IL purchased a new stake in Vical in the 4th quarter valued at about $2,579,000. Perceptive Advisors LLC purchased a new stake in Vical in the 4th quarter valued at about $2,091,000. Stonepine Capital Management LLC purchased a new stake in Vical in the 4th quarter valued at about $1,238,000. Finally, Sabby Management LLC purchased a new stake in Vical in the 4th quarter valued at about $503,000. Hedge funds and other institutional investors own 47.25% of the company’s stock.
Vical Company Profile
Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.